Coventry, UK, 8th May 2017 / Medherant Ltd, a University of Warwick spin-out company developing a novel transdermal drug delivery patch technology, has appoin
8th May 2017
6th February 2017
Coventry, UK, 6th February 2017 / Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, is pleased t
27th September 2016
Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, has completed a funding round worth £1.5M, including a direct investment of £650,000 from Mercia Technologies PLC.
8th July 2016
Medherant were recently shortlisted for the ON Helix BioNewsRound 2016 Award; an award which recognises the biotech related press releases which have had the most impact over the previous year.
5th May 2016
Mercia has committed follow-on capital to Medherant Ltd. Medherant’s patch, known as the TEPI-patch®, is a thin, strong, easy-to-apply and easy-to-remove patch capable of delivering higher doses of drugs.
22nd February 2016
Researchers at the University of Warwick have worked with Coventry-based Medherant, a Warwick spinout company, to produce and patent the World’s first ever ibuprofen patch deli
22nd February 2016
Ibuprofen Patch Heralds Side Effect Free Drug Future
1st February 2016
As universities have become better at organising their theoretical research into commercial propositions, intermediaries have appeared on the scene to nurture their research until it is ready to be commercialised.
2nd November 2015
We had over 30 very encouraging partnering meetings with companies who could be potential investors or development partners
8th June 2015
New bio-adhesive company Medherant, founded by Warwick Ventures for the University of Warwick, UK, in 2014, has signed a license agreement with the leading global adhesive specialists Bostik.